What Omnigen does

Omnigen SA is a privately held Greek biotechnology company, incorporated as a Societe Anonyme and headquartered in Marousi, Athens, that has operated since 2006 in stem cell cryopreservation, cell therapies, and regenerative medicine. The company functions as a family cord blood and tissue bank, isolating and cryopreserving hematopoietic stem cells from umbilical cord blood (OMNI-BLOOD) and mesenchymal stem cells from umbilical cord tissue (OMNI-CORD), and offers a combined bundle (OMNI-PLUS). Operations run through GMP/GLP-compliant laboratories with cryopreservation at temperatures below -150°C in monitored tanks, using ISBT-128 international coding for sample traceability and a continuing-storage contractual clause that guarantees transfer to another licensed EU bank upon termination.

The company holds several first-mover regulatory positions in Greece: the first private cord blood bank licensed by the Ministry of Health (License C2c/31238, renewed June 2026), the first bank approved by the National Transplant Organization (EOM) for tissue cryopreservation, and the first Greek biobank recognized by the European body for Tissue and Cell Banks (EU TE Code GR012775). It is accredited to ISO 9001:2015 by Lloyd's Register, to ELOT EN ISO/IEC 17025:2005 under ESYD (No. 560), and operates quality systems harmonized with FACT and JACIE international standards. Beyond storage, Omnigen offers an in-house diagnostic portfolio: Thrombophilia Screening via Real-Time PCR TaqMan genotyping, Cystic Fibrosis Examination via direct DNA sequencing and an Abbott CFTR assay covering 202 mutations, and, through a partnership with Veragen/Veracity, non-invasive prenatal testing (VERAGEN) that simultaneously screens for aneuploidies, microdeficiencies, and gene mutations.

The commercial model is direct-to-consumer and sales-led, targeting expectant parents and prenatal patients through a bilingual website (Greek/English), Facebook and YouTube channels, email marketing, and on-site consultations at the Marousi office or at customer locations. Healthcare providers (obstetricians and hospitals) act as referral partners and coordinate sample collection at the point of childbirth. Revenue is generated via multi-year subscription contracts (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS) billed on multi-year cadences plus professional-services fees for diagnostic testing. Payments are accepted by bank deposit, cash, credit card with up to six interest-free installments, and online payment via Alpha e-Commerce. EU ESPA funding for the 2021-2027 period is disclosed, but no headcount growth, funding rounds, M&A, or revenue figures are publicly available.

Name

Omnigen

Legal name

OMNIGEN ΒΙΟΤΕΧΝΟΛΟΓΙΚΕΣ ΕΦΑΡΜΟΓΕΣ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ

Website

https://omnigen.gr

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Omnigen is a Greece-based, licensed family cord blood and tissue bank that processes and cryopreserves umbilical cord blood and tissue stem cells (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS), and serves expectant parents and prenatal healthcare patients with diagnostic services and NIPT screening in partnership with Veragen.

Ownership category

akta.pro rank

Product category

Stem Cell Banking and Cryopreservation Services

NAICS

Blood and Organ Banks (621991), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Cord blood banking
• Stem cell cryopreservation
• Regenerative medicine
• Prenatal diagnostic testing
• Cell therapy services

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Stem Cell Cryopreservation Services: Core revenue stream from processing and cryopreserving hematopoietic stem cells from umbilical cord blood and cord tissue. Services include collection kit provision, transportation, processing, cryopreservation, and ongoing storage for the contract duration.
2. Diagnostic Testing Services: Revenue from thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAgene) services performed in their accredited laboratories.
3. OMNI-BLOOD, OMNI-CORD, OMNI-PLUS Packages: Different service packages offering cord blood storage, cord tissue storage, or combined storage solutions at varying price points with the OMNI-PLUS package offering special pricing for combined services.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Omnigen is a licensed Greek cord blood bank that provides collection, processing, cryopreservation, and long-term storage of hematopoietic stem cells from umbilical cord blood and mesenchymal stem cells from umbilical cord tissue for family use. The company also offers diagnostic laboratory services including thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAGEN) for expectant parents.

Product overview

Omnigen is a licensed cord blood bank and biotechnology company offering a portfolio of stem cell banking and diagnostic services. The core offering consists of OMNI-BLOOD (cord blood stem cell cryopreservation), OMNI-CORD (umbilical cord tissue storage for mesenchymal stem cells), and OMNI-PLUS (a combined package of both services). The company also provides diagnostic laboratory services including Thrombophilia Screening using Real-Time PCR methodology, Cystic Fibrosis Examination through CFTR gene mutation analysis, and VERAGEN Non-Invasive Prenatal Testing for aneuploidies, microdeficiencies, and gene mutations. The company operates as a family cord blood storage bank licensed by the Greek Ministry of Health, serving clients in Greece with collection, processing, cryopreservation, and storage services for umbilical cord blood and tissue.

Differentiator

Problem solved

Functional benefit

Brands

• OMNI-BLOOD: Cord blood collection service including transportation, processing, cryopreservation and storage of umbilical cord blood stem cells.
• OMNI-CORD
• OMNI-PLUS
• VERAGEN

Products and services

• OMNI-BLOOD Cord blood collection and cryopreservation service that isolates and cryopreserves hematopoietic stem cells from umbilical cord blood, processed in modern laboratories and stored at temperatures below -150°C in high-quality cryobags with 24-hour monitoring and remote alarm systems. Targets expectant parents in Greece seeking family banking for potential future therapeutic use.
• OMNI-CORD Umbilical cord tissue storage service that processes and cryopreserves the cord tissue to isolate and store valuable multipotent mesenchymal cells for future medical use in regenerative medicine applications. Targets expectant parents seeking additional stem cell sources beyond cord blood.
• OMNI-PLUS Combined cryopreservation package that includes both OMNI-BLOOD (umbilical cord blood stem cells) and OMNI-CORD (umbilical cord tissue) services at a special price, providing both hematopoietic and mesenchymal stem cells available for regenerative medicine. Includes free transportation of both samples in case of illness.
• Thrombophilia Screening Genetic diagnostic test that detects thrombophilic factors using Real-Time PCR methodology (TaqMan assay genotyping) to identify hypercoagulability conditions in blood circulation that can lead to clot formation and pregnancy complications. Targets pregnant women and individuals with family history of clotting disorders.
• Cystic Fibrosis Examination Genetic screening test for cystic fibrosis that detects pathogenic mutations in the CFTR gene through direct DNA sequencing and the Abbott Cystic Fibrosis Genotyping Assay, covering 202 pathogenic mutations representing 90% of recorded mutations in international databases. Targets couples planning for or during pregnancy to assess carrier status.
• VERAGEN (Non-Invasive Prenatal Testing) Non-invasive prenatal test (NIPT) that simultaneously screens for aneuploidies, microdeficiencies, and gene mutations from a maternal blood sample, with results delivered in 4-7 business days. The test uses maternal blood and paternal oral swab samples collected by doctors at least 10 weeks into pregnancy. The only NIPT in the Greek market combining all three screening types.

Quantifiable outcome

• 59% lower likelihood of developing serious adverse events (GVHD) in recipients of umbilical cord blood transplants compared to bone marrow transplants from siblings
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Veragen / VeracitycoreTechnology or IntegrationOmnigen offers VERAgene non-invasive prenatal testing (NIPT) for aneuploidies, microdeficiencies, and gene mutations. This is the only non-invasive prenatal test that can simultaneously screen for these three types of genetic conditions. Omnigen performs the laboratory analysis of maternal blood samples and paternal oral swabs collected by doctors at least 10 weeks into pregnancy.
• Theodoros MoumourisminorOthersSigned official GMP compliance document dated June 28, 2011, related to the company's laboratory operations and regulatory compliance.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Cells4Life: UK-based private cord blood and tissue bank offering family stem cell storage across multiple countries in Europe. Directly comparable to Omnigen in business model (B2C family banking, recurring storage contracts), accreditation stack, and service mix including NIPT-adjacent diagnostics.
• Precious Cells International: UK-based private stem cell bank offering cord blood and tissue storage with multi-year contracts. Directly comparable to Omnigen in operating model and customer segment (expectant parents seeking family banking).
• Biohellenika: Greek biotechnology company operating a stem cell and cord blood bank in Thessaloniki. Directly comparable to Omnigen as a Greek competitor in the same cord blood banking category, addressing the same domestic customer base.
• Future Health Biobank: One of Europe's largest private stem cell banks, offering cord blood, cord tissue, and other cell storage with multi-year contracts. Closely comparable to Omnigen on service model, customer base (expectant parents), and regulatory positioning across European markets.
• Smart Cells International: UK-based private cord blood stem cell bank serving expectant parents in the UK and internationally. Closely comparable to Omnigen as a direct-to-consumer family cord blood storage operator with multi-year storage contracts and obstetrician referral channels.
• AlphaCord: US private cord blood bank offering family storage of umbilical cord blood and tissue. Comparable to Omnigen as a direct-to-consumer private cord blood storage operator with subscription-style contracts.

Broad incumbents

• Cryo-Cell International: US-listed public cord blood bank with decades of operating history and a broader product portfolio across family banking and therapeutic services. Comparable as a scaled, publicly disclosed private-market peer in the family cord blood banking category.
• ViaCord: US-based cord blood and cord tissue bank (part of Revvity/PerkinElmer) offering family stem cell storage. Comparable as a large incumbent in the same product category with broader portfolio scale and brand recognition than Omnigen.
• Cord Blood Registry (CBR): One of the largest US family cord blood banks, now part of California Cryobank. Comparable as a broad incumbent in the same family cord blood banking category with significantly larger scale and brand reach than Omnigen.

Regional players

• StemCare: Nordic-focused private cord blood and tissue stem cell bank serving Northern European markets. Comparable to Omnigen in service offering and family banking model, but operating in a different geography from Omnigen's Greek market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCIr3eyGQuZbKCEv56urOXMQ
• Facebookfacebook.com/omnigen
• Xx.com/OmnigenSA
• LinkedInlinkedin.com/company/omnigen-s-a-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omnigen